Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

March 2, 2028

Study Completion Date

March 2, 2029

Conditions
IgA Nephropathy (IgAN)
Interventions
DRUG

Avacopan

Avacopan is a complement 5a receptor (C5aR) antagonist, orally active.

DRUG

Prednisone

0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months

DRUG

Methylprednisolone (drug)

Methylprednisolone 1g intravenous on day +1

DRUG

Prednisolone

Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)

Trial Locations (2)

32224

RECRUITING

Mayo Clinic in Florida, Jacksonville

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06676579 - Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) | Biotech Hunter | Biotech Hunter